Has Marshall Stoller, MD received payments from drug or device companies?

Yes. Drug and device makers reported $290,062 in general payments to Marshall Stoller, MD across 81 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marshall Stoller, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marshall Stoller, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marshall Stoller, MD

Urology · San Francisco, CANPI 1104854512

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $245,146 of the $290,062 with a category attached, or 84.5%. Johnson & Johnson accounts for 91.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $215,344 and has fallen 99.7% since, to $697 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$290,062in general payments, 2019–2025

Across 81 payments — averaging $3581.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$264K
Novo Nordisk$11K
OTU Medical Inc.$10K
C. R. Bard, Inc. & Subsidiaries$2K
Boston Scientific$2K
Hitachi Healthcare Americas Corp.$248
plus $686 from 5 others

$607,747in research payments, 2019–2025

Across 75 payments — averaging $8103.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$400K
Novo Nordisk US Research & Development, Inc.$208K

What the payments were for

Consulting fees$39,82814%
Speaking & faculty fees$245,14685%
Travel & lodging$1,1900%
Food & beverage$3,6511%
Entertainment$2480%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	27	$264,183
Novo Nordisk	13	$10,803
OTU Medical Inc.	1	$10,000
C. R. Bard, Inc. & Subsidiaries	17	$2,225
Boston Scientific	13	$1,916
Hitachi Healthcare Americas Corp.	3	$248
KARL Storz Endoscopy-america	2	$212
Urogen Pharma, Inc.	2	$197
Novo Nordisk Health Care AG	1	$124
Cook Medical LLC	1	$114
Coloplast	1	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Monarch Platform$20,200
Rivfloza$1,632
GENERAL KIDNEY STONE DISEASE$1,116
Bard Urinary Drainage Bag$1,000
THERAPIES$164
JELMYTO$155
Bard InLay Optima Ureteral Stent with HydroGlide Guidewire$136
LithoVue$135
LITHO 150$114
HD-VIEW$104

How this compares

$290,062 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024

$188,565

Medicare patients

542

Services billed

1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	11	$10,319
Potassium Citrate ErPotassium Citrate	49	$7,900
Tamsulosin Hcl	132	$2,356
Finasteride	71	$806
Chlorthalidone	27	$798
Solifenacin Succinate	14	$507
Oxybutynin Chloride	12	$395
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	14	$203
Hydrochlorothiazide	11	$94

Paid to pharmacies, not to this prescriber.

Other urology in San Francisco

Matthew CooperbergSan Francisco$86K
Stephen FreedlandWest Hollywood$1.9M
Arie BelldegrunLos Angeles$1.8M
Mihir DesaiLos Angeles$1.5M
Steven WilsonIndio$1.1M
Stuart HoldenLos Angeles$1.1M
Elward CrawfordSan Diego$849K
Edward UchioOrange$849K
Victor ChingUpland$809K
Jaime LandmanOrange$657K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →